GlobeNewswire·Nov 5, 2026, 4:05 PM ET

RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million

RNXT

RenovoRx reported third-quarter 2026 revenue of $1.07 million, representing a four-fold year-over-year increase.
The company expanded its active commercial cancer center customer base to 26 centers from 21 in the previous quarter.
The total commercial funnel grew to more than 65 centers, with a year-end 2026 target of 36 active sites.
RenovoRx maintained its full-year 2026 revenue guidance range of $3.75 million to $4.25 million.
Gross profit reached $878,000 with an approximate 82% gross margin for the quarter.
Research and development expenses were approximately $1.2 million, while selling, general, and administrative expenses totaled approximately $2.9 million.
The company recorded a net loss of $0.08 per share, consistent with the same period in 2025.
Cash and cash equivalents increased to approximately $10.4 million as of September 30, 2026.
The Phase III TIGeR-PaC trial achieved full enrollment in August 2026, with initial top-line data expected in the second half of 2027.
Physician-driven expansion occurred beyond locally advanced pancreatic cancer, including the first commercial use for sarcoma treatment in August 2026.
The first patient was enrolled in October 2026 for the PRISM-TAMP Investigator Initiated Trial at the University of Vermont.
Two peer-reviewed publications were released in the third quarter supporting the TAMP platform's safety, efficacy, and pharmacokinetic data.
The U.S. Patent and Trademark Office issued a Notice of Allowance for a new patent covering the RenovoCath dual-occlusion catheter system in August 2026.